Review
Copyright ©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 145-155
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.145
Table 1 Properties of commercially available botulinum toxin drugs
Botox®Dysport®Xeomin®NeuroBloc® Myobloc®
ManufacturerAllergan Inc. Irvine, CA, United StatesIpsen Pharma Boulogne-Billancourt, FranceMerz Pharmaceuticals Frankfurt/M, GermanyUnited States WorldMeds Louisville, KY, United States
Pharmaceutical preparationPowderPowderPowderReady-to-use solution 5000 MU-E/mL
Storage conditionsBelow 8 °CBelow 8 °CBelow 25 °CBelow 8 °C
Shelf life36 mo24 mo36 mo24 mo
Botulinum toxin typeAAAB
Clostridium botulinum strainHall AIpsen strainHall ABean B
SNARE targetSNAP25SNAP25SNAP25VAMP
Purification processPrecipitation and chromatographyPrecipitation and chromatographyPrecipitation and chromatographyPrecipitation and chromatography
pH-value of the reconstituted preparation7.47.47.45.6
StabilisationVacuum dryingFreeze-drying (lyophilisate)Vacuum dryingpH-reduction
ExcipientsHuman serum albumin 500 μg/100 MU-vial; NaCl 900 μg/100 MU-vial buffer systemHuman serum albumin 125 μg/500 MU-vial; Lactose 2500 μg/100 MU-vial buffer systemHuman serum albumin 1000 μg/100 MU-vial; Sucrose 4.7 mg/100 MU-vial buffer systemHuman serum albumin 500 μg/mL; Disodium succinate 0.01 mol/L; Sodium chloride 0.1 mol/L; H2O; Hydrochloric acid
Biological activity50/100 MU-A/vial500 MU-I/vial50/100 MU-M/vial1.0/2.5/10.0 kMU-E/vial
Biological activity in relation to Botox®11:2-1:311:40
Specific biological activity60 MU-EV/ngBNT100 MU-EV/ngBNT167 MU-EV/ngBNT5 MU-EV/ngBNT